Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maternal pertussis vaccination and infant immune response to primary acellular pertussis vaccination
NL-OMON48434Phase 4Withdrawn
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Sep 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pertussis filamentous haemagglutinin and tdap vaccine in pertussis (2 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Pertussis toxin-specific antibody geometric mean concentration at 6 months. Planned start Sep 2019; status: withdrawn.
02
Drugs
pertussis filamentous haemagglutinintdap vaccine
03
Conditions
pertussis
Beyond the preview
Go deeper on NL-OMON48434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48434.